222 related articles for article (PubMed ID: 19349520)
21. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
[TBL] [Abstract][Full Text] [Related]
22. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam.
Le MT; Wertheim HF; Nguyen HD; Taylor W; Hoang PV; Vuong CD; Nguyen HL; Nguyen HH; Nguyen TQ; Nguyen TV; Van TD; Ngoc BT; Bui TN; Nguyen BG; Nguyen LT; Luong ST; Phan PH; Pham HV; Nguyen T; Fox A; Nguyen CV; Do HQ; Crusat M; Farrar J; Nguyen HT; de Jong MD; Horby P
PLoS One; 2008 Oct; 3(10):e3339. PubMed ID: 18836532
[TBL] [Abstract][Full Text] [Related]
23. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus.
Shu M; Lin Z; Zhang Y; Wu Y; Mei H; Jiang Y
J Mol Model; 2011 Mar; 17(3):587-92. PubMed ID: 20517627
[TBL] [Abstract][Full Text] [Related]
26. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
Nguyen HT; Chesnokov A; De La Cruz J; Pascua PNQ; Mishin VP; Jang Y; Jones J; Di H; Ivashchenko AA; Killian ML; Torchetti MK; Lantz K; Wentworth DE; Davis CT; Ivachtchenko AV; Gubareva LV
Antiviral Res; 2023 Sep; 217():105679. PubMed ID: 37494978
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
[TBL] [Abstract][Full Text] [Related]
28. Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.
Ilyushina NA; Bovin NV; Webster RG
J Virol; 2012 May; 86(9):4724-33. PubMed ID: 22379077
[TBL] [Abstract][Full Text] [Related]
29. [Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors].
Chen Z; Zheng YH; Lin Y; Collins PJ; Hay AJ
Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(27):1924-8. PubMed ID: 20979914
[TBL] [Abstract][Full Text] [Related]
30. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.
Nguyen HT; Nguyen T; Mishin VP; Sleeman K; Balish A; Jones J; Creanga A; Marjuki H; Uyeki TM; Nguyen DH; Nguyen DT; Do HT; Klimov AI; Davis CT; Gubareva LV
Emerg Infect Dis; 2013 Dec; 19(12):1963-71. PubMed ID: 24274711
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
[TBL] [Abstract][Full Text] [Related]
33. Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
Adams SE; Lee N; Lugovtsev VY; Kan A; Donnelly RP; Ilyushina NA
Antiviral Res; 2019 Sep; 169():104539. PubMed ID: 31228489
[TBL] [Abstract][Full Text] [Related]
34. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Hurt AC; Holien JK; Barr IG
Antimicrob Agents Chemother; 2009 Oct; 53(10):4433-40. PubMed ID: 19651908
[TBL] [Abstract][Full Text] [Related]
35. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.
Baranovich T; Burnham AJ; Marathe BM; Armstrong J; Guan Y; Shu Y; Peiris JM; Webby RJ; Webster RG; Govorkova EA
J Infect Dis; 2014 May; 209(9):1343-53. PubMed ID: 24133191
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
[TBL] [Abstract][Full Text] [Related]
37. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
Marathe BM; Mostafa HH; Vogel P; Pascua PNQ; Jones JC; Russell CJ; Webby RJ; Govorkova EA
Antiviral Res; 2017 Dec; 148():20-31. PubMed ID: 29100887
[TBL] [Abstract][Full Text] [Related]
38. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus.
Naughtin M; Dyason JC; Mardy S; Sorn S; von Itzstein M; Buchy P
Antimicrob Agents Chemother; 2011 May; 55(5):2004-10. PubMed ID: 21343450
[TBL] [Abstract][Full Text] [Related]
39. Computational studies of H5N1 influenza virus resistance to oseltamivir.
Wang NX; Zheng JJ
Protein Sci; 2009 Apr; 18(4):707-15. PubMed ID: 19309695
[TBL] [Abstract][Full Text] [Related]
40. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Kiso M; Takahashi K; Sakai-Tagawa Y; Shinya K; Sakabe S; Le QM; Ozawa M; Furuta Y; Kawaoka Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):882-7. PubMed ID: 20080770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
